Golimumab market seen topping $33 billion by 2030

The Simponi and Simponi Aria market is forecast to grow to more than $33 billion by 2030, driven by rising autoimmune disease treatment demand and wider biologic use. North America is expected to remain the largest regional market, while Johnson & Johnson holds the entire 2025 market share in the report's view.

Why it matters: - The Simponi and Simponi Aria market sits inside the fast-growing autoimmune biologics space, where treatment access, dosing convenience and biosimilar competition can reshape patient costs and adoption. - The market's projected climb to more than $33 billion by 2030 signals continued demand for tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.

What happened: - The Business Research Company projected the global Simponi and Simponi Aria (golimumab) market will exceed $33 billion by 2030, rising at an 8% compound annual growth rate. - The report said North America will remain the largest regional market in 2030 at $14 billion, up from $10 billion in 2025. - The United States is expected to be the biggest country market in the region, reaching $13 billion in 2030 from $9 billion in 2025. - Johnson & Johnson held 100% of the market share in 2025, according to the report.

The details: - Simponi and Simponi Aria are golimumab biologics available in subcutaneous and intravenous forms. - The therapies are used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and other immune-mediated inflammatory diseases. - The report said golimumab makes up about 68% of the broader tumor necrosis factor inhibitor drugs market. - That wider TNF inhibitor market is projected to reach nearly $48 billion by 2030. - Within the broader pharmaceuticals sector, estimated at $2,496 billion by 2030, the golimumab segment would account for close to 1% of total value. - By type, the report said type I will lead in 2030 with 41% of the market, or $14 billion. - The report also listed type II, type III and type IV as the other segments. - By administration route, the market is split between subcutaneous injection and intravenous infusion. - By indication, the market covers rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis. - By application, the report points to hospital and clinic settings. - The report said the market's growth is being supported by rising autoimmune disease prevalence, broader biologic adoption and more convenient dosing. - Once-monthly self-administered Simponi and physician-managed Simponi Aria infusions are cited as adoption drivers.

Between the lines: - The market remains highly concentrated because biologics face complex manufacturing, strict regulation, long clinical development cycles and strong intellectual property protection. - Biosimilars could pressure pricing and expand access, especially as more commercialization deals emerge. - In May 2024, Bio-Thera Solutions partnered with STADA Arzneimittel AG on BAT2506, a golimumab biosimilar for Europe. - Johnson & Johnson's dominance suggests the category is still shaped more by originator control than broad competitive fragmentation. - Merck & Co. Inc. was cited as another company with a strong position through its biologics portfolio and immunology work.

What's next: - The report expects type segments I through IV to add more than $10.1 billion in value by 2030. - Type II is forecast to add $5 billion, type I $4 billion, type III $1 billion and type IV $0.1 billion between 2025 and 2030. - North American growth is tied to higher autoimmune diagnosis rates, wider reimbursement, specialty care expansion and increased use of self-administered biologics. - The report points to patient support programs, regulatory expansion and geographic growth as key strategies for market participants.

The bottom line: - Golimumab remains a large, concentrated biologics market with North America in the lead and biosimilar competition starting to build around the edges.